biotech · Non small cell lung cancer · oligometastatic hormone sensitive prostate cancer · CERO
CERo Therapeutics
CERO THERAPEUTICS HOLDINGS, INC.
CERo Therapeutics is a biotech organization headquartered in South San Francisco, USA. It trades on NYSE under ticker CERO. Primary therapeutic focus areas include Non small cell lung cancer, oligometastatic hormone sens
Company details
- Status
- Public
- HQ
- 201 Haskins Way, 230, South San Francisco, California 94080, US
- Employees
- 17
- Programs
- 47
- Drugs
- 84
- Patents
- 14
MEDI4736 Placebo, DURVALUMAB
Phase 3 · small molecule · Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients
MEDI4736 Placebo, DURVALUMAB for Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients is a Phase 3 program (small_molecule) at CERO THERAPEUTICS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).
Internal code BR31
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CERO THERAPEUTICS HOLDINGS, INC.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients
- Status
- active
- Trials
- 1